CD56-positive large B-cell lymphoma

Applied Immunohistochemistry and Molecular Morphology

Volumn 14, Issue 4, 2006, Pages 369-374

  Weisberger, James ^a   Gorczyca, Wojciech ^b   Kinney, Marsha C ^c  

^a BioReference Laboratories   (United States)

^b Genzyme Genetics   (United States)

^c University of Texas Health Science Center   (United States)

Author keywords

B cell; CD56; Flow cytometry; Immunohistochemistry; Immunophoenotyping

Indexed keywords

CD56 ANTIGEN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; B LYMPHOCYTE DIFFERENTIATION; CELL STRUCTURE; CLINICAL ARTICLE; CLINICAL FEATURE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MALE; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD56; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LYMPHOMA, B-CELL; MALE; MIDDLE AGED;

EID: 33751366308     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/01.pai.0000208279.66189.43     Document Type: Article

References (33)

1. Robertson MJ, Ritz J. Biology and clinical relevance of human natural killer cells. Blood. 1990;76:2421-2438.
2. Lanier LI, Le AM, Civin CI, et al. The relationship of CD16 (Leu-11) and Leu-9 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J Immunol. 1986;136:4480-4486.
3. Griffin JD, Herend T, Beveridge RP, et al. Characterization of an antigen expressed by human natural killer cells. J Immunol. 1983;130:2947-2951.
4. Jaffe ES, Chan JKC, Su I-J. Report of the workshop on nasal and related extranodal angiocentric T/natural killer cell lymphomas: definitions, differential diagnosis and epidemiology. Am J Surg Pathol. 1996;20:103-111.
5. Wong KF, Chan JKC, Ng CS, et al. CD56 (NKHI)-positive hematolymphoid malignancies: an aggressive neoplasm featuring frequent cutaneous/mucosal involvement, cytoplasmic azurophilic gruanules, and angiocentricity. Hum Pathol. 1992;23:798-804.
6. Van Camp B, Durie BGM, Spier C, et al. Plasma cells in multiple myelomas express a natural killer cell-associated antigen: CD56 (NKH-1;Leu-19). Blood. 1990;76:377-382.
7. Kwong YL, Chan CL, Liang R, et al. CD56+ NK lymphomas, clinicopathological features and prognosis. Br J Haematol. 1997;97:821-829.
8. Delgado J, Morado M, Jimenez MC, et al. CD56 expression in myeloperoxidase-negative FAB M5 acute myeloid leukemia. Am J Hematol. 2002;69:28-30.
9. Jaffe ES. Classification of natural killer (NK) cell and NK-like T-cell malignancies. Blood. 1996;87:1207-1210.
10. Mann KP, DeCastro CM, Liu J, et al. Neural cell adhesion molecule (CD56)-positive acute myelogenous leukemia and myelodysplastic and myeloproliferative syndromes. Am J Clin Pathol. 1997;107:653-660.
11. Tsang WY, Chan JK, Pau MY. Utility of a paraffin section-reactive CD56 antibody (123C#) for characterization and diagnosis of lymphomas. Am J Surg Pathol. 1996;20:202-210.
12. Wong KF, Chan JKC, Ng CS. CD56 (NCAM) positive malignant lymphoma. Leuk Lymphoma. 1994;14:29-36.
13. Hammer R, Vnencak-Jones CL, Manning SS, et al. Microvillous lymphomas are B-cell neoplasms that frequently express CD56. Mod Pathol. 1998;11:239-246.
14. Sekita T, Tamaru J, Isobe K, et al. Diffuse large B-cell lymphoma expressing the natural killer marker CD56. Pathol Int. 1999;49:752-758.
15. Ogmundsdottir HM, Thorsteinsson L, Sigfusson A, et al. Natural killer cell function and malignant cell phenotype in hairy cell leukemia. APMIS. 1992;100:10-20.
16. Stelzer G, Marti G, Hurley A, et al. US-Canadian consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: standardization and validation of laboratory procedures. Cytometry. 1997;30:214-230.
17. Steward CC, Behm FG, Carey JL, et al. US-Canadian consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: selection of antibody combinations. Cytometry. 1997;30:231-235.
18. Dong HY, Gorczyca W, Liu Z, et al. B-Cell Lymphomas With Coexpression of CD5 and CD10. Am J Clin Pathol. 2003;119:218-230.
19. Ng CS, Chan JKC, Lo STH. Expression of natural killer cell markers in non-Hodgkin's lymphomas. Hum Pathol. 1987;18:1257-1262.
20. Spier CM, Miller TP, et al. NCAM (CD56)-positive malignant lymphoma. Leuk Lymphoma. 1993;12:1-10.
21. Rutishauer U, Acheson A, Hall AK, et al. The neural adhesion molecule (NCAM) as a regulator of cell-cell interactions. Science. 1988;240:53-57.
22. Ely SA, Knowles DM. Expression of CD56/neural cell adhesion molecule correlates with the presence of lytic bone lesions in multiple myeloma and distinguishes myeloma from monoclonal gammopathy of undetermined significance and lymphomas with plasmacytoid differentiation. Am J Pathol. 2002;160:1293-1299.
23. Sahara N, Takeshita A, Shigeno K. Clinicopathological and prognostic characteristics of CD56-negative multiple myeloma. Br J Haematol. 2002;117:882-885.
24. Pellat-Deceunyck C, Barille S, Jego G, et al. The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma. Leukemia. 1998;12:1977-1982.
25. Patel K, Frost G, Rossell R, et al. Expression of the neural adhesion molecule (NCAM) on the haematopoietic line NALM-16. Leuk Res. 1992;16:307-315.
26. Young HE, Steele TA, Bray RA, et al. Human pluripotent and progenitor cells display cell surface cluster differentiation markers CD10, CD13, CD56, and MHC class-I. Proc Soc Exp Biol Med. 1999;221:63-71.
27. Reynaud D, Lefort M, Manie E, et al. In vitro identification of pro-B cells that give rise to macrophages, natural killer cells, and T cells. Blood. 2002;101:4313-4321.
28. Chen W, Iida S, Louie DC, et al. Heterologous promoters fused to BCL6 by chromosomal translocations affecting band 3q27 cause its deregulated expression during B-cell differentiation. Blood. 1998;91:603-607.
29. Peng HZ, Du MQ, Koulis A, et al. Nonimmunoglobulin gene hypermutation in germinal center B-cells. Blood. 1999;93:2167-2172.
30. Lai R, Weiss LM, Chang KL, et al. Frequency of CD43 expression in non-Hodgkin lymphoma. A survey of 742 cases and further characterization of rare CD43+ follicular lymphomas. Am J Clin Pathol. 1999;111:488-494.
31. Delsol G, Lamant L, Mariame B, et al. A new subtype of large B-cell lymphoma expressing ALK kinase and lacking the 2;5 translocation. Blood. 1997;89:1483-1490.
32. Hamilton KS, Vnencak-Jones CL, Swerdlow SH, et al. CD30+ B-cell lymphomas: a morphologic, immunophenotypic, and molecular study. Mod Pathol. 1999;12:138A.
33. Kinney MC, Glick AD, Stein H, et al. Comparison of anaplastic large cell Ki-1 lymphomas and microvillous lymphomas in their immunologic and ultrastructural features. Am J Surg Pathol. 1990;14:1047-1060.